Increasing Social Media Use in Urology: 2017 American Urological Association Survey.

The use of social media is growing rapidly in health care. The purpose of this study was to provide updated data on utilization of social media in urology. A survey was emailed to 19 840 American Urological Association (AUA) members in September 2017, and responses were compared to our previous survey in 2013.

Effect of the American Urological Association Annual Review course on the results of the urology qualifying examination.

Purpose: In this study we assess the impact of a urology dedicated review course on the scores of the corresponding board qualifying examination for attendees of the urology review course.

Materials And Methods: The ABU (American Board of Urology) Qualifying Examination scores from 2009, 2010 and 2011 were categorized into group 1 candidates who attended the AUA (American Urological Association) Annual Review Course the same year, and group 2 candidates who did not attend the AUA Annual Review Course that same year, and were compared. The scores of the preceding year's In-Service Examination were also compared for the same groups of candidates and compared to their subsequent first time taken Qualifying Examination scores.

Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.

A dihydroquinolinone moiety was found to be a potent serotonin reuptake inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D(2) ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D(2) partial agonists and serotonin reuptake inhibitors. Structure-activity studies revealed that the linker plays a key role in contributing to D(2) affinity, function, and SRI activity.

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.

A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.